The presentation will be webcast live from the Investor section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available through
About Adamas Pharmaceuticals, Inc.
Adamas develops new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Parkinson's disease, multiple sclerosis, epilepsy and Alzheimer's disease. Adamas has pioneered a platform to develop medicines, called chrono-synchronous therapies, for chronic neurologic disorders based on an understanding of the time-dependent biologic processes responsible for disease activity and drug response to potentially achieve symptomatic relief without tolerability issues. The company's most advanced product candidate, ADS-5102, is in development for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and walking impairment. An NDA supporting ADS-5102 for the treatment of LID in patients with Parkinson's disease is under review by the
NAMENDA XR® and NAMZARIC® are trademarks of
Martin ForrestVice President, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc.510-450-3528 email@example.com
News Provided by Acquire Media